Abstracts tagged "Gene Expression"

Abstract Number: 2878 • 2014 ACR/ARHP Annual Meeting
G Protein Signaling Modulator 3 (GPSM3) Deficiency Is Protective in Inflammatory Arthritis Models and Altered GPSM3 Gene Products Correlate with Single Nucleotide Polymorphisms in Humans
Teresa K. Tarrant¹, D. Stephen Serafin², Elizabeth Sugg², Roman Timoshchenko², Matthew J. Billard², David P. Siderovski³ and Kristy Richards⁴, ¹Medicine/Rheumatology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Physiology and Pharmacology, West Virginia University School of Medicine, Morgantown, WV, ⁴Medicine, Dept. of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose GPSM3, a newly described regulator of heterotrimeric G protein signaling, is selectively expressed in hematopoietic cells with high expression in monocytes. We have shown…
Abstract Number: 1619 • 2014 ACR/ARHP Annual Meeting
Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs
David Drubin¹, Xiang Guo², Linglin Yang³, Rong Zeng³, Yuling Wu³, Mustimbo EliPollard Roberts³, Reynald Lescarbeau¹, Aaron Van Hooser¹, Michael Macoritto¹, Michelle Petri⁴ and Wendy White⁵, ¹Selventa, Cambridge, MA, ²Translational Sciences, MedImmune LLC, Gaithersburg, MD, ³MedImmune LLC, Gaithersburg, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose Interferons (IFNs) have long been implicated in the pathogenesis of systemic lupus erythematosus (SLE). However, the specific consequences of the IFN activity have not…
Abstract Number: 2798 • 2014 ACR/ARHP Annual Meeting
C5orf30 a Novel Regulator of Inflammation and Tissue Damage in Rheumatoid Arthritis
Munitta Muthana¹, Sarah Hawtree¹, Holly Davies², Hannah Roberts¹, Sachin Khetan¹, Mohammed Akil³, Fiona Wright¹, Barbara Ciani⁴, Ursula Fearon⁵, DJ Veale⁶ and Anthony G. Wilson⁷, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²University of Sheffield, Sheffield, United Kingdom, ³Rheumatology Department, Sheffield South Yorkshire, United Kingdom, ⁴Chemistry, University of Sheffield, Sheffield, United Kingdom, ⁵Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ⁶Consultant Rheumatologist, St. Vincent’s University Hospital, Dublin, Ireland, ⁷Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose A recent genome wide association study identified the variant rs26232 in the first intron of the uncharacterized gene, C5orf30, as a rheumatoid arthritis (RA)…
Abstract Number: 1617 • 2014 ACR/ARHP Annual Meeting
Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes
Zhongbo Jin¹, Mark A. Jensen², Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin³, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁶, Kevin G. Moder⁴, Vaidehi Chowdhary³ and Timothy B. Niewold¹, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁶Dept of Rheumatology, Mayo Clinc, Rochester, MN
Background/Purpose Type I interferon (IFN) is a primary pathogenic factor in human systemic lupus erythematosus (SLE). IFN gene expression signatures have been observed in whole blood and mixed peripheral…
Abstract Number: 2687 • 2014 ACR/ARHP Annual Meeting
Estrogen-Mediated STAT1 Activation By Estrogen Receptor a Induces TLR8 Expression: A Novel Pathogenic Mechanism in Systemic Lupus Erythematosus
Nicholas Young¹, Giancarlo Valiente², Lai-Chu Wu³, Michael Bruss⁴, Stacy Ardoin², Craig Burd⁵ and Wael N. Jarjour⁶, ¹Ohio State University, Columbus, OH, ²Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Molecular & Cellular Biochemistry, The Ohio State University, Columbus, OH, ⁶Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Many autoimmune disorders, including Systemic Lupus Erythematosus (SLE) display female gender predominance. Previous studies have demonstrated significant hormonal contributions to SLE pathogenesis, including estrogen,…
Abstract Number: 1517 • 2014 ACR/ARHP Annual Meeting
Analysis of Gene Expression Fluctuation with Abatacept Highlights the Involvement of the Proteasome Pathway As a Mechanism of Action of Abatacept in Rheumatoid Arthritis
C Derambure¹, O Vittecoq^1,2, G Dzangue Tchoupou¹, Maria-Antonietta d'Agostino³, P Gaudin⁴, C Gaillez⁵, M Le Bars⁶ and T Lequerré^1,2, ¹Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²Department of Rheumatology, Rouen University Hospital, Rouen, France, ³AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁴Department of Rheumatology, University Hospital Grenoble, Grenoble, France, ⁵Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Abatacept (ABA) is a biologic therapy targeting T cells, which play a major role in the pathophysiology of RA. Overall, 57.1% of patients reached…
Abstract Number: 2566 • 2013 ACR/ARHP Annual Meeting
Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Tammara A. Wood², Robert F. Spiera¹ and Michael L. Whitfield², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Gene expression profiling by DNA microarray is used to identify potential biomarkers in Systemic Sclerosis (SSc). Discrete gene expression signatures have been observed to…
Abstract Number: 1175 • 2013 ACR/ARHP Annual Meeting
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Nicola Dalbeth¹, Meaghan House², Gregory Gamble², Bregina Pool¹, Anne Horne², Lauren Purvis², Angela Stewart², Marilyn E. Merriman³, Murray Cadzow⁴, Amanda Phipps-Green³ and Tony R. Merriman³, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout. This gene encodes a high-capacity urate transporter expressed in the intestine,…
Abstract Number: 2501 • 2013 ACR/ARHP Annual Meeting
Validation Of Gene Expression Biomarkers Of Psoriatic Arthritis
Fatima Abji¹, Remy Pollock¹, Fawnda Pellett², Kun Liang³, Vinod Chandran² and Dafna D. Gladman², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a seronegative immune mediated arthritis that develops in about a third of patients with cutaneous psoriasis (PsC). The cellular pathways…
Abstract Number: 1171 • 2013 ACR/ARHP Annual Meeting
Treatment Of Psoriasis Patients With IMO-3100 Shows Improvement In Gene Expression Patterns Of Meta-Analysis Derived-3 Transcriptome and IL-17 Pathway
Mayte Suarez-Farinas¹, Jennifer Belasco¹, Tim Sullivan², Robert Arbeit² and James G. Krueger¹, ¹Krueger Laboratory, The Rockefeller University, New York, NY, ²Idera Pharmaceuticals, Inc., Cambridge, MA

Background/Purpose: IMO‑3100, an antagonist of TLRs 7 and 9, has shown significant improvement in Psoriasis Area and Severity Index (PASI) scores in a randomized, double‑blind,…
Abstract Number: 2403 • 2013 ACR/ARHP Annual Meeting
The Incidence Of Factor V Leiden A1691G, Methylene Tetrahydrofolate Reductase C677T, and Prothrombin G20210A Mutation In Patients With Rheumatoid Arthritis
Taskin Senturk¹, Zahit Bolaman², Sabri Batun³, Irfan Yavasoglu⁴ and Gurhan Kadikoylu², ¹Adnan Menderes University, Department of Rheumatology, Professor, Aydin, Turkey, ²Adnan Menderes University, Department of Hematology, Professor, Aydin, Turkey, ³Dicle University, Department of Hematology, Professor, Diyarbakır, Turkey, ⁴Adnan Menderes University, Department of Hematology, Associated Professor, Aydin, Turkey
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic and inflammatory disease. Thromboembolic phenomenas are more frequent in patients with RA than healthy individuals and several…
Abstract Number: 934 • 2013 ACR/ARHP Annual Meeting
Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts
Koji Fukuda¹, Yasushi Miura^1,2, Toshihisa Maeda¹, Shinya Hayashi³ and Masahiro Kurosaka³, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand (FasL), LIGHT,…
Abstract Number: 2190 • 2013 ACR/ARHP Annual Meeting
Clinical and Immunologic Description Of Pediatric Conditions With Interferon-Regulated Gene Signatures (Chronic Atypical Neutrophilic Dermatosis Lipodystrophy Elevated Tempature, Aicardi Goutieres Syndrome, Juvenile Dermatomyositis, Juvenile Systemic Lupus Erythematosus)
Hanna Kim¹, Adriana Almeida de Jesus², Yin Liu³, Yan Huang¹, Gina Montealegre⁴, Dawn Chapelle⁵, Nicole Plass¹, Wanxia Tsai⁶, Massimo Gadina⁷, Lisa G. Rider⁸, Adeline Vanderver⁹ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD, ³Translational Autoinflammatory Disease Section, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁴Office of the Clinical DIrector, NIAMS / NIH, Bethesda, MD, ⁵Office of the Clinical Director, NIAMS / NIH, Bethesda, MD, ⁶Translational Immunology Section, NIAMS / NIH, Bethesda, MD, ⁷Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁸Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁹Pediatric Neurology, Children's National Medical Center, Washington, DC
Background/Purpose: Increased interferon (IFN) regulated gene (IRG) expression has been reported in juvenile systemic lupus (JSLE)1 and juvenile dermatomyositis (JDM)2. Recently, two monogenic conditions chronic…
Abstract Number: 721 • 2013 ACR/ARHP Annual Meeting
T Cell Activation Induces Increased mRNA Expression Of The Splicing Factor SF2/ASF But Simultaneous Protein Downregulation Via Proteasome Mediated Degradation
Vaishali R. Moulton¹, Andrew R. Gillooly¹ and George C. Tsokos², ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) are poor producers of the vital cytokine interleukin (IL)-2. We recently showed that SLE…
Abstract Number: 2201 • 2013 ACR/ARHP Annual Meeting
Exon and miRNA Arrays Reveal Complexity and Specificity Of The Juvenile Idiopathic Arthritis Neutrophil Transcriptome
Zihua Hu¹, Kaiyu Jiang², Mark B. Frank³, Yanmin Chen² and James N. Jarvis², ¹Center for Computational Research, University at Buffalo, Buffalo, NY, ²Pediatrics, The University at Buffalo, Buffalo, NY, ³Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Data from the NIH Roadmap Epigenomics and ENCODE projects have revealed unexpected richness in mammalian transcriptomes. Large regions the genome that do not encode…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].